Last updated on November 2017

The Immunologic Effects of HCV Therapy with Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.


Brief description of study

The Immunologic Effects of HCV Therapy with Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.

Detailed Study Description

The body’s immune system usually becomes active when the body is fighting off an infection or disease. If an immune system is active for a long period of time, it may lead to problems such as heart, liver, and kidney disease. Many people who inject drugs are also infected with the Hepatitis C virus (HCV). We have found that people who inject drugs have evidence of an activated immune system. We do not know whether the activated immune system we have measured is due to HCV infection or due to injection of drugs. In this study, we will compare the immune systems of people infected with HCV who are actively injecting drugs and those who are not injecting drugs before and after treating the HCV infection with a new oral medication, HARVONI. This is a combination of the medications Ledipasvir and Sofosbuvir. The reason for doing this research is to understand how HCV and injecting drugs contribute to the activation of the immune system and if treating HCV will decrease this activation.

Clinical Study Identifier: TX6133

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

The Rockefeller University Hospital

The Rockefeller University Hospital
New York, NY USA
  Connect »